BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6447707)

  • 1. Potency of the effect of D-stereoisomer of aminoglutethimide on adrenal and extraadrenal steroidogenesis.
    Samojlik E; Santen RJ
    J Clin Endocrinol Metab; 1980 Sep; 51(3):462-5. PubMed ID: 6447707
    [No Abstract]   [Full Text] [Related]  

  • 2. Adrenal suppression with aminoglutethimide. II. Differential effects of aminoglutethimide on plasma androstenedione and estrogen levels.
    Samojlik E; Santen RJ; Wells SA
    J Clin Endocrinol Metab; 1977 Sep; 45(3):480-7. PubMed ID: 903399
    [No Abstract]   [Full Text] [Related]  

  • 3. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
    Harris AL; Dowsett M; Jeffcoate SL; Smith IE
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
    Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
    J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
    Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
    Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
    Dowsett M; Harris AL; Smith IE; Jeffcoate SL
    J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
    Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
    Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
    Santen RJ; Samojlik E; Lipton A; Harvey H; Ruby EB; Wells SA; Kendall J
    Cancer; 1977 Jun; 39(6 Suppl):2948-58. PubMed ID: 194681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine treatment of breast cancer: effects upon intratumoral estrone sulfate metabolism and peripheral steroid levels.
    Carlström K; Pousette A; Rannevik G; Sköldefors H; Theve NO; Wilking N
    Breast Cancer Res Treat; 1986; 7 Suppl():S107-9. PubMed ID: 2943337
    [No Abstract]   [Full Text] [Related]  

  • 10. Aminoglutethimide in the treatment of advanced breast cancer.
    Stuart-Harris RC; Smith IE
    Cancer Treat Rev; 1984 Sep; 11(3):189-204. PubMed ID: 6241038
    [No Abstract]   [Full Text] [Related]  

  • 11. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate S
    Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
    Samojlik E; Santen RJ
    J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical adrenalectomy and plasma steroids in advanced breast carcinoma.
    Newsome HH; Brown PW; Terz JJ; Lawrence W
    Surgery; 1978 Jan; 83(1):83-9. PubMed ID: 619476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How effective is surgical adrenalectomy in lowering steroid hormone concentrations?
    Worgul TJ; Santen RJ; Samojlik E; Wells SA
    J Clin Endocrinol Metab; 1982 Jan; 54(1):22-6. PubMed ID: 6459336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast.
    Samojlik E; Santen RJ; Kirschner MA; Ertel NH
    Cancer Res; 1982 Aug; 42(8 Suppl):3349s-3352s. PubMed ID: 7083199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose aminoglutethimide in treatment of advanced breast cancer.
    Stuart-Harris R; Dowsett M; Bozek T; McKinna JA; Gazet JC; Jeffcoate SL; Kurkure A; Carr L; Smith IE
    Lancet; 1984 Sep; 2(8403):604-7. PubMed ID: 6147642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenal suppression with aminoglutethimide. I. Differential e-fects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone.
    Santen RJ; Wells SA; Runić S; Gupta C; Kendall J; Rudy EB; Samojlik E
    J Clin Endocrinol Metab; 1977 Sep; 45(3):469-79. PubMed ID: 198423
    [No Abstract]   [Full Text] [Related]  

  • 18. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
    Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
    Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cigarette smoking and levels of adrenal androgens in postmenopausal women.
    Khaw KT; Tazuke S; Barrett-Connor E
    N Engl J Med; 1988 Jun; 318(26):1705-9. PubMed ID: 2967432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.